Clinical trials: Advanced Solid Tumors Patients
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054288
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors, Excluding Breast Cancer
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.
This is a multi-center, open-label, single-sequence, crossover, drug-drug interaction (DDI) study to assess the effect of the CYP1A2 inhibitor, fluvoxamine, on the PK of dovitinib in patients with advanced solid tumors, excluding…
- Trial name
- CTKI258A2120 (NCT01700270)
- Testing
- dovitinib (TKI258), fluvoxamine
- Where
- 6 sites in United States, Denmark and 2 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Solid Tumours, Carcinoma Non-small Cell Lung
First in Human Study of AZD9592 in Solid Tumors
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary…
- Conditions
- Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
- Trial name
- EGRET (NCT05647122)
- Testing
- AZD9592, Osimertinib, 5-Fluorouracil (5-FU)
- Where
- 46 sites in United States, Australia and 9 more
- Volunteers
- 190 people
- Sponsor
- AstraZeneca
Locally Advanced/Metastatic Solid Tumors
First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study
First-in-Human, Phase I, open-label, multicenter, dose-escalation study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of FL115 in patients with advanced solid tumors who have…
- Trial name
- NCT06130722
- Testing
- FL115
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Suzhou Forlong Biotechnology Co., Ltd
Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC)
Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Evaluate the safety and antitumor activity of JYP0015 in adults with specific RAS mutant advanced solid tumors.
- Conditions
- Solid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
- Trial name
- STAR (NCT06895031)
- Testing
- JYP0015
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Advanced Solid Tumors
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation and cohort expansion study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of IMM2510(Anti-PD-L1 and VEGF trap recombinant…
- Trial name
- NCT07170787
- Testing
- IMM2510, IMM01
- Where
- China
- Volunteers
- 104 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Unspecified Adult Solid Tumor, Protocol Specific
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function.
- Trial name
- NCT00003706
- Testing
- pemetrexed disodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Solid Tumor
A First-in-human Dose-escalation and Expansion Study With the Antibody-drug Conjugate BYON3521
This is the first-in-human trial with BYON3521, an antibody-drug conjugate (ADC) comprising a humanized IgG1 monoclonal antibody directed against the c-MET receptor covalently conjugated to a duocarmycin-containing linker-drug.
- Trial name
- NCT05323045
- Testing
- BYON3521
- Where
- 4 sites in Belgium, Italy and 2 more
- Volunteers
- 31 people
- Sponsor
- Byondis B.V.
Pancreatic Neoplasms, Solid Tumors
Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder. This is a study for people for whom previous treatment was not successful or no treatment exists.
- Conditions
- Pancreatic Neoplasms, Solid Tumors, Biliary Tract Cancer, Lung Neoplasms
- Trial name
- NCT05512377
- Testing
- Brigimadlin
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 99 people
- Sponsor
- Boehringer Ingelheim
Brain and Central Nervous System Tumors, Breast Cancer
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Brain and Central Nervous System Tumors, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00019019
- Testing
- carboxyamidotriazole, paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Selected Advanced Solid Tumors, Colorectal Cancer (CRC)
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
This Phase 1, open-label study will evaluate two investigational radiopharmaceuticals in adults with selected advanced or metastatic solid tumors.
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC)
- Trial name
- NCT07812805
- Testing
- SKL35501, SKL35502
- Where
- 5 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- SK Life Science, Inc.
Advanced Solid Tumor
TR64 in Patients With Advanced Solid Tumors
This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when administered qd in patients with advanced solid…
- Trial name
- NCT05649345
- Testing
- TR64
- Where
- 2 sites in China
- Volunteers
- 19 people
- Sponsor
- Tarapeutics Science Inc.
Advanced Solid Tumors
A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors
This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.
- Trial name
- NCT06929663
- Testing
- AK146D1 for injection
- Where
- Australia
- Volunteers
- 48 people
- Sponsor
- Akeso
Cancer, Advanced Solid Tumor
StrataPATH™ (Precision Indications for Approved Therapies)
StrataPATH™ is a non-randomized, open-label trial designed to explore efficacy and safety of multiple FDA-approved and commercially available cancer therapies in new, biomarker-guided patient populations.
- Trial name
- StrataPATH (NCT05097599)
- Testing
- lorlatinib, encorafenib + binimetinib, talazoparib
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Strata Oncology
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors
The purpose of the trial is to establish the tolerability of tisotumab vedotin (HuMax-TF-ADC) dosed three times every four weeks (3q4wk) in a mixed population of patients with specified solid tumors.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT02552121
- Testing
- Tisotumab vedotin (HuMax-TF-ADC)
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 33 people
- Sponsor
- Seagen Inc.
Recurrent Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors
This phase I/II trial is studying the side effects and best dose of obatoclax mesylate when given together with topotecan hydrochloride and to see how well they work in treating patients with relapsed or refractory small cell…
- Trial name
- NCT00521144
- Testing
- obatoclax mesylate, topotecan hydrochloride, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Metastatic Colorectal Cancer
Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and 5-fluorouracil in patients with advanced solid tumors.
- Trial name
- NCT01238939
- Testing
- NK012 and 5-FU
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Advanced Breast Cancer
Study of DM5167 in Patients With Advanced Solid Tumors
DM5167 is a second-generation of PARP inhibitor that selectively targets the PARP-1 enzyme. This results in less haematological toxicity and a high level of safety.
- Trial name
- NCT07101601
- Testing
- DM5167
- Where
- 4 sites in South Korea
- Volunteers
- 58 people
- Sponsor
- DIGMBIO
Neoplasms
This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)
This study is open to adults with different types of advanced cancer (solid tumors). The purpose of this study is to find out the most suitable dose of BI 907828 (brigimadlin) the participants can tolerate.
- Trial name
- NCT03449381
- Testing
- BI 907828
- Where
- 27 sites in United States, Belgium and 9 more
- Volunteers
- 266 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Malignancies
Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid Malignancies
This is a phase I, open-label study to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of AZD9150 monotherapy and AZD9150 in combination with durvalumab in Japanese patients with advanced…
- Trial name
- NCT03394144
- Testing
- AZD9150, Durvalumab
- Where
- 2 sites in Japan
- Volunteers
- 11 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.